Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study

被引：17

作者：

Bazinet, M. ^{[1
]}

Pantea, V. ^{[2
]}

Cebotarescu, V. ^{[2
]}

Cojuhari, L. ^{[2
]}

Jimbei, P. ^{[3
]}

Vaillant, A. ^{[1
]}

机构：

[1] Replicor Inc, Montreal, PQ, Canada

[2] Nicolae Testemitanu State Univ Med & Pharm, Kishinev, Moldova

[3] Toma Ciorba Infect Clin Hosp, Kishinev, Moldova

来源：

关键词：

D O I：

10.1016/S0168-8278(18)31266-2

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

FRI-326

引用

页码：S509 / S509

页数：1